PARP1 and hepatocellular carcinoma: Therefore, the loss or inhibition of PARP in combination with cisplatin demonstrates greater growth suppression of HCC and OSCC cell lines, reduced cell viability in OAC and a synergistic effect in CRC cell lines, when compared to the cisplatin-only control groups [96,123,129,130,131].